Darbepoetin α, a long-acting erythropoeitin derivate, does not alter lps evoked myocardial depression and gene expression of BAX, bcl-xs, bcl-xl, bcl-2, and TNF-α

Shock

Volumn 31, Issue 1, 2009, Pages 50-54

  Brendt, Peter ^a   Frey, Ulrich ^a   Adamzik, Michael ^a   Schäfer, Simon T ^a   Peters, Jürgen ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Darbepoetin ; Endotoxin; Gene expression; Langendorff apparatus; Left ventricular function; Septic cardiomyopathy

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART PERFUSION; ISOLATED HEART; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROSPECTIVE STUDY; RAT; REAL TIME POLYMERASE CHAIN REACTION; SEPSIS; TISSUE SECTION; UPREGULATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; CARDIOMYOPATHIES; DRUG RESISTANCE; ERYTHROPOIETIN; GENE EXPRESSION REGULATION; HEMATINICS; LIPOPOLYSACCHARIDES; MALE; MYOCARDIUM; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED LEW; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 58849144706     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/SHK.0b013e31817c0188     Document Type: Article

References (39)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B: Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 168: 165-172, 2003.
2. Parrillo JE: Pathogenetic mechanisms of septic shock. N Engl J Med 328: 1471-1477, 1993.
3. Parrillo JE: The cardiovascular pathophysiology of sepsis. Annu Rev Med 40: 469-485, 1989.
4. Parker MM, Shelhamer JH, Bacharach SL, Green MV, Natanson C, Frederick TM, Damske BA, Parrillo JE: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483-490, 1984.
5. Pathan N, Hemingway CA, Alizadeh AA, Stephens AC, Boldrick JC, Oragui EE, McCabe C, Welch SB, Whitney A, O'Gara P, et al.: Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363: 203-209, 2004.
6. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M: Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 28:1631-1639, 19%.
7. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 257:387-389, 1992.
8. Meldrum DR: Tumor necrosis factor in the heart. Am J Physiol 274: R577-R595, 1998.
9. Kapadia S, Lee J, Torre-Amione G, Birdsall HH, Ma TS, Mann DL: Tumor necrosis factor-alpha gene and protein expression in adult feline myocardium after endotoxin administration. J Clin Invest 96:1042-1052, 1995.
10. Turner A, Tsamitros M, Bellomo R: Myocardial cell injury in septic shock. Crit Care Med 27:1775-1780, 1999.
11. Petillot P, Lahorte C, Bonanno E, Signore A, Lancel S, Marchetti P, Vallet B, Siegers G, Neviere R: Annexin V detection of lipopolysaccharide- induced cardiac apoptosis. Shock 21:69-14, 2007.
12. Fauvel H, Marchetti P. Chopin C, Formstecher P, Neviere R: Differential effects of caspase inhibitors on endotoxin-induced myocardial dysfunction and heart apoptosis. Am J Physiol Heart Circ Physiol 280:H1608-H1614, 2001.
13. Neviere R, Fauvel H, Chopin C, Formstecher P, Marchetti P: Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis. Am J Respir Crit Care Med 163:218-225, 2001.
14. McDonald TE, Grinman MN, Carthy CM, Walley KR: Endotoxin infusion in rats induces apoptotic and survival pathways in hearts. Am J Physiol Heart Circ Physiol 279:H2053-H2061, 2000.
15. Orkin SH, Weiss MJ: Apoptosis. Cutting red-cell production. Nature 401:433, 435-436, 1999.
16. Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, Thompson RB, Petrofski JA, Annex BH, Stamler JS, et al.: A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007, 2003.
17. Villa P, Bigini P, Mennini T, Agnello D, Laragione T, Cagnotto A, Viviani B, Marinovich M, Cerami A, Coleman TR, et al.: Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971-975, 2003.
18. Vesey DA, Cheung C, Pat B, Endre Z, Gobe G, Johnson DW: Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 19: 348-355, 2004.
19. Zhande R, Karsan A: Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am J Physiol Heart Circ Physiol 292:H2467-H2474, 2007.
20. Koroglu TF, Yilmaz O, Ozer E. Baskin H, Gokmen N, Kumral A. Duman M. Ozkan H: Erythropoietin attenuates lipopolysaccharide-induced splenic and thymic apoptosis in rats. Physiol Res 55:309-316, 2006.
21. Joy MS: Darbepoetin alfa: a novel erythropoiesis-stimulaling protein. Ann Pharmacother 36:1183-1192, 2002.
22. Baker JE, Kozik D, Hsu AK, Fu X, Tweddell JS, Gross GJ: Darbepoetin alfa protects the rat heart against infarction: dose-response, phase of action, and mechanisms. J Cardiovasc Pharmacol 49:337-345, 2007.
23. Gao E. Boucher M, Chuprun JK, Zhou RH, Eckhart AD, Koch WJ: Darbepoetin alfa. a long-acting erythropoietin analog, offers novel and delayed cardio-protection for the ischemic heart. Am J Physiol Heart Circ Physiol 293: H60-H68, 2007.
24. Frey UH, Eisenhardt A, Lummen G, Rubben H. Jockel KH. Schmid KW. Siffert W: The T393C polymorphism of the G alpha s gene (GNASI) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Prev 14:871-877, 2005.
25. Bachmann HS, Siffert W, Frey UH: Successful amplification of extremely GC-rich promoter regions using a novel 'slowdown PCR" technique. Pharmacogenetics 13:759-766, 2003.
26. Celik M, Gokmen N, Erbayraktar S. Akhisaroglu M, Konakc S. Ulukus C. Gene S, Gene K, Sagiroglu E, Cerami A, et al.: Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci USA 99:2258-2263, 2002.
27. Abdelrahman M. Sharpies EJ, McDonald MC. Collin M. Patel NS. Yaqoob MM, Thiemermann C: Erythropoietin attenuates the tissue injury associated with hemorrhagic shock and myocardial ischemia. Shock 22:63-69. 2004.
28. Huang CH, Hsu CY, Chen HW, Tsai MS, Cheng HJ, Chang CH, Lee YT. Chen WJ: Erythropoietin improves the postresuscitation myocardial dysfunction and survival in the asphyxia-induced cardiac arrest model. Shock 28:53-58. 2007.
29. Bullard AJ, Govewalla P, Yellon DM: Erythropoietin protects the myocardium against reperfusion injury in vitro and in vivo. Basic Res Cardiol 100:397-403. 2005.
30. Calvillo L, Latini R, Kajstura J, Leri A, Anversa P, Ghezzi P, Salio M, Cerami A, Brines M: Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802-4806. 2003.
31. Lipsic E, van der Meer P, Henning RH, Suurmeijer AJ, Boddeus KM. van Veldhuisen DJ, van Gilst WH, Schoemaker RG: Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 44:473-479, 2004.
32. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K: Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 291:H748-H755. 2006.
33. Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV. Tomita D, Rossi G: Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol 24:2290-2297, 2006.
34. Le Minh K, Klemm K, Abshagen K, Eipel C, Menger MD, Vollmar B: Attenuation of inflammation and apoptosis by pre- and posttreatment of darbepoetin-alpha in acute liver failure of mice. Am J Pathol 170:1954-1963, 2007.
35. Lancel S, Petillot P, Favory R, Stebach N, Lahorte C, Danze PM. Vallet B. Marchetti P, Neviere R: Expression of apoptosis regulatory factors during myocardial dysfunction in endotoxemic rats. Crit Care Med 33:492-4%, 2005.
36. Comstock KL, Krown KA, Page MT, Martin D. Ho P, Pedraza M, Castro EN, Nakajima N, Glembotski CC, Quintana PJ, et al.: LPS-induced TNF-alpha release from and apoptosis in rat cardiomyocytes: obligatory role for CD14 in mediating the LPS response. J Mol Cell Cardiol 30:2761-2775, 1998.
37. Liu X, Xie W, Liu P, Duan M, Jia Z, Li W, Xu J: Mechanism of the cardioprotection of rhEPO pretreatment on suppressing the inflammatory response in ischemia-reperfusion. Life Sci 78:2255-2264, 2006.
38. Haudek SB, Spencer E, Bryant DD, White DJ, Maass D, Horton JW, Chen ZJ. Giroir BP: Overexpression of cardiac I-kappaBalpha prevents endotoxin-induced myocardial dysfunction. Am J Physiol Heart Circ Physiol 280:H962-H968. 2001.
39. Brown MA, Jones WK: NF-kappaB action in sepsis: the innate immune system and the heart. Front Biosci 9:1201-1217, 2004.